$LIVN

LivaNova (NASDAQ: LIVN) officer to sell 1,650 shares

LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell 1,650 shares of common stock under Rule 144, valued at $131,538. The shares stem from vested restricted stock units awarded in 2023 and 2024. Bianchi also sold 1,800 shares in May 2026 and 1,200 shares in June 2026.

Original reporting
Published Aug 31, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 4:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LIVN
Bearish
medium confidence
Mentioned
$LIVN
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LIVNBearishLow
01

Why it matters

A modest insider sale may cause short‑term price softness but is unlikely to alter long‑term outlook.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Recent prior sales by the same officer and overall insider ownership levels could mitigate any negative perception.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 144 filings disclose planned insider sales under Rule 144, signaling potential new share supply.

Company-level read

Ticker impact

$LIVNBearishMedium confidence
Context

Officer Francesco Bianchi filed a Form 144 to sell 1,650 shares worth $131,538, adding supply to the market.

Expected impact

Potential short-term dip of 0.5‑1% as the market digests the new supply.

Evidence & confidence

The sale size is small relative to total shares outstanding, but insider sales are often viewed as a bearish signal.

Market effects

Minimal; the sale does not affect the broader medical device sector.

Limited to U.S. investors holding LIVN.

Low; no cross‑border or macro implications.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals, so price impact may be negligible.

Key entities

  • Francesco Bianchi

    LivaNova officer filing the sale.

Related articles

$LIVNMed

LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.

$LIVNMedAI 8/10

A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.